New evidence demonstrates link between smoking, prostate cancer prognosis
the ONA take:
The association between smoking and the development of various forms of cancer are well established; however, evidence of such a link with prostate cancer is contradictory.
Now, an international study led by MedUni Vienna and Basle University Hospital has found evidence of a clear link.
The study combined data on 7,191 patients with prostate cancer who underwent radical prostatectomy, with no preoperative treatments.
The results showed that risk of biochemical recurrence of prostate for smokers and ex-smokers was twice that of nonsmokers. However, this negative effect can be offset within 10 years of quitting.
Although this research still does not clarify, in scientific terms, whether smoking is associated with the development of prostate cancer, it does demonstrate that smoking increases the risk of dying from the disease.
The researchers acknowledge that further research is needed, but stress the significance of quitting smoking even for those who are already suffering from prostate cancer.
Association between smoking and development of various forms of cancer well established; however, evidence of prostate cancer link contradictory.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|